標(biāo)題: Titlebook: Combination Cancer Therapy; Modulators and Poten Gary K. Schwartz Book 2005 Humana Press 2005 Chemotherapie.apoptosis.carcinoma.cell.leukem [打印本頁(yè)] 作者: 切口 時(shí)間: 2025-3-21 17:41
書(shū)目名稱(chēng)Combination Cancer Therapy影響因子(影響力)
書(shū)目名稱(chēng)Combination Cancer Therapy影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Combination Cancer Therapy網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Combination Cancer Therapy網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Combination Cancer Therapy被引頻次
書(shū)目名稱(chēng)Combination Cancer Therapy被引頻次學(xué)科排名
書(shū)目名稱(chēng)Combination Cancer Therapy年度引用
書(shū)目名稱(chēng)Combination Cancer Therapy年度引用學(xué)科排名
書(shū)目名稱(chēng)Combination Cancer Therapy讀者反饋
書(shū)目名稱(chēng)Combination Cancer Therapy讀者反饋學(xué)科排名
作者: 冒號(hào) 時(shí)間: 2025-3-21 21:18
Cancer Drug Discovery and Developmenthttp://image.papertrans.cn/c/image/229856.jpg作者: Outmoded 時(shí)間: 2025-3-22 03:59
https://doi.org/10.1385/1592598641Chemotherapie; apoptosis; carcinoma; cell; leukemia; ovarian cancer作者: 附錄 時(shí)間: 2025-3-22 08:15 作者: 北京人起源 時(shí)間: 2025-3-22 10:19 作者: 擦掉 時(shí)間: 2025-3-22 13:47
,Modelling “Nano-Effects” in Sintering,ath process (apoptosis) (.) and progress in the development of molecularly targeted agents directed against specific oncogenes and enzymes responsible for neoplastic transformation, e.g., STI571 in the case of Bcr/Abl+ malignancies (.). Such efforts have served to focus attention on two general clas作者: 擦掉 時(shí)間: 2025-3-22 17:52 作者: gregarious 時(shí)間: 2025-3-22 21:35 作者: 詢(xún)問(wèn) 時(shí)間: 2025-3-23 02:07
Role of Grain Boundaries in Sinteringornerstone of present-day developmental chemotherapy. From its rational synthesis by Heidelberger in 1957 (.) to quantification of the molecular determinants of fluorinated pyrimidine (fluoropyrimidine) activity, our understanding of fluoropyrimidine pharmacology has helped mold our concepts of ever作者: Mendicant 時(shí)間: 2025-3-23 07:28 作者: NEG 時(shí)間: 2025-3-23 10:21
Recrystallization and Sintering in Ceramicsment of resistance impacts the utility of the drug in many patients, particularly in the setting of recurrent disease. Although the exact mechanism of cisplatin resistance needs to be delineated, it is widely accepted that multiple factors may contribute to cisplatin resistance.作者: 孤僻 時(shí)間: 2025-3-23 16:37
https://doi.org/10.1007/978-94-009-0741-6ological processes, especially in the immune and nervous systems, and in development (.,.). Deregulation of apoptosis can lead to autoimmune diseases, cancer, and the clinical manifestations of acquired immunodeficiency syndrome (AIDS) (.).作者: Charade 時(shí)間: 2025-3-23 18:34 作者: 填滿(mǎn) 時(shí)間: 2025-3-24 02:03
,Targeting NF-κB to Increase the Activity of Cisplatin in Solid Tumors,ment of resistance impacts the utility of the drug in many patients, particularly in the setting of recurrent disease. Although the exact mechanism of cisplatin resistance needs to be delineated, it is widely accepted that multiple factors may contribute to cisplatin resistance.作者: JADED 時(shí)間: 2025-3-24 05:29 作者: 尊嚴(yán) 時(shí)間: 2025-3-24 10:32
Combination Cancer Therapy978-1-59259-864-9Series ISSN 2196-9906 Series E-ISSN 2196-9914 作者: 公共汽車(chē) 時(shí)間: 2025-3-24 11:32
Recrystallization and Sintering in Ceramicsment of resistance impacts the utility of the drug in many patients, particularly in the setting of recurrent disease. Although the exact mechanism of cisplatin resistance needs to be delineated, it is widely accepted that multiple factors may contribute to cisplatin resistance.作者: aerobic 時(shí)間: 2025-3-24 17:16
https://doi.org/10.1007/978-94-009-0741-6ological processes, especially in the immune and nervous systems, and in development (.,.). Deregulation of apoptosis can lead to autoimmune diseases, cancer, and the clinical manifestations of acquired immunodeficiency syndrome (AIDS) (.).作者: 誘惑 時(shí)間: 2025-3-24 21:37
https://doi.org/10.1007/978-3-7091-3951-6oses that fully inhibit receptor signaling, and single-agent activity has been observed against a variety of tumor types, including colon carcinoma, non-small-cell lung cancer (NSCLC), head and neck cancer, ovarian carcinoma, and renal-cell carcinoma. However, their antitumor activity is significant作者: Hiatal-Hernia 時(shí)間: 2025-3-25 02:21 作者: 柱廊 時(shí)間: 2025-3-25 06:58
Role of Grain Boundaries in Sintering it infrequently results in improved survival—the end-point that probably matters most. Pharmacological modulation of any drug revolves around understanding those critical relationships between biochemical targets in the cell, and how we can exploit their underlying biology in a way that renders any作者: BIPED 時(shí)間: 2025-3-25 11:25
Computer Simulation of Sintering Processesegulated by signals received from the environment (.). Signals may come from interactions with other cells or components of the extracellular matrix, or from binding of soluble signaling molecules to specific receptors at the cell membrane, thereby initiating different signaling pathways inside of t作者: 反復(fù)無(wú)常 時(shí)間: 2025-3-25 13:20 作者: allude 時(shí)間: 2025-3-25 19:06 作者: 豐富 時(shí)間: 2025-3-25 22:22
Pharmacological Modulation of Fluoropyrimidines, it infrequently results in improved survival—the end-point that probably matters most. Pharmacological modulation of any drug revolves around understanding those critical relationships between biochemical targets in the cell, and how we can exploit their underlying biology in a way that renders any作者: 錯(cuò) 時(shí)間: 2025-3-26 00:28
Use of Animal Models to Evaluate Signal Transduction Inhibitors As Modulators of Cytotoxic Therapy,egulated by signals received from the environment (.). Signals may come from interactions with other cells or components of the extracellular matrix, or from binding of soluble signaling molecules to specific receptors at the cell membrane, thereby initiating different signaling pathways inside of t作者: Fatten 時(shí)間: 2025-3-26 06:12
Targeting of the EGFR As a Modulator of Cancer Chemotherapy,ors. In human tumors, receptor overexpression correlates with a more aggressive clinical course. These observations suggest that the EGFR is a promising target for cancer therapy, and monoclonal antibodies directed at the ligand-binding extracellular domain and low molecular weight (MW) inhibitors o作者: 向宇宙 時(shí)間: 2025-3-26 08:37
Cyclin-Dependent Kinase Inhibitors in Combination Chemotherapy, carcinogenesis. This novel class of anticancer therapeutics exploits these perturbations to achieve tumor-specific cytotoxicity. In the last several years, our understanding of cell-cycle regulation has improved with the emerging concepts of cell-cycle-mediated drug resistance and cell-cycle modula作者: hemorrhage 時(shí)間: 2025-3-26 13:05 作者: 吼叫 時(shí)間: 2025-3-26 16:49
Carboxyamidotriazole, an Inhibitor of Nonvoltage-Operated Calcium Entry,ency have been made, improvement in cure rate for advanced-stage cancers remains unchanged. This sobering statistic has led investigators to search for novel targets and intervention combinations for the prevention and treatment of cancer. The advent of combination carboplatin/paclitaxel for the adj作者: Genetics 時(shí)間: 2025-3-26 22:56
,Targeted α-Particle Therapy,mab (Rituxan; IDEC Pharmaceuticals, San Diego, CA, and Genentech, Inc., South San Francisco, CA), trastuzumab (Herceptin; Genentech, Inc., South San Francisco, CA), and alemtuzumab (Campath-1H; Burroughs Wellcome, United Kingdom)—have been approved by the US Food and Drug Administration (FDA) for th作者: leniency 時(shí)間: 2025-3-27 05:04
Pharmacological Modulation of Fluoropyrimidines,ornerstone of present-day developmental chemotherapy. From its rational synthesis by Heidelberger in 1957 (.) to quantification of the molecular determinants of fluorinated pyrimidine (fluoropyrimidine) activity, our understanding of fluoropyrimidine pharmacology has helped mold our concepts of ever作者: ENDOW 時(shí)間: 2025-3-27 06:44
Development of Inhibitors of HER2 With Taxanes,ically treatable but not curable, the primary goal of clinical management is often to create an optimal equilibrium between maximizing response, minimizing toxicity, improving survival, and optimizing symptom palliation. The search for new drugs that might provide these characteristics, together wit作者: Transfusion 時(shí)間: 2025-3-27 13:11
,Targeting NF-κB to Increase the Activity of Cisplatin in Solid Tumors,ment of resistance impacts the utility of the drug in many patients, particularly in the setting of recurrent disease. Although the exact mechanism of cisplatin resistance needs to be delineated, it is widely accepted that multiple factors may contribute to cisplatin resistance.作者: 滲透 時(shí)間: 2025-3-27 13:55 作者: 按時(shí)間順序 時(shí)間: 2025-3-27 19:54
Use of Animal Models to Evaluate Signal Transduction Inhibitors As Modulators of Cytotoxic Therapy, and respond to in “programmed” patterns (.). As the understanding of cancer has increased, the complexity of the molecular events that comprise malignant disease has become evident (.). Interactions involved in intertwining signaling networks including membrane receptors, enzymes along with activat作者: Harness 時(shí)間: 2025-3-28 01:23
2196-9906 erapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cyc作者: 前面 時(shí)間: 2025-3-28 05:46
Recrystallization and Sintering in Ceramicsr novel targets and intervention combinations for the prevention and treatment of cancer. The advent of combination carboplatin/paclitaxel for the adjuvant treatment of ovarian cancer has led to improved response rates and prolonged survival (.). However, over 60% of patients relapse, and the 5-yr survival rate is still below 50%.作者: NAG 時(shí)間: 2025-3-28 09:28 作者: FRONT 時(shí)間: 2025-3-28 12:16
Book 2005future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (作者: Precursor 時(shí)間: 2025-3-28 17:36
2196-9906 d breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient‘s bedside for the future treatments in cancer therapy.978-1-62703-806-5978-1-59259-864-9Series ISSN 2196-9906 Series E-ISSN 2196-9914 作者: 異教徒 時(shí)間: 2025-3-28 22:48 作者: 投票 時(shí)間: 2025-3-28 22:58 作者: 欲望 時(shí)間: 2025-3-29 04:27 作者: 逃避現(xiàn)實(shí) 時(shí)間: 2025-3-29 08:59
Book 2005PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient‘s bedside for the future treatments in cancer therapy.作者: Slit-Lamp 時(shí)間: 2025-3-29 11:59
https://doi.org/10.1007/978-3-7091-3951-6tion to improve cytotoxic drug efficacy. It is becoming increasingly apparent that CDKIs may improve cytotoxic drug efficacy by functioning as cell-cycle modulators. In this chapter, we review the field of CDKIs as novel anticancer therapeutics, with a focus on their efficacy in drug combinations.作者: 時(shí)代 時(shí)間: 2025-3-29 18:06
R. C. Garvie,R. H. Hannink,R. T. Pascoee treatment of lymphoma, breast cancer, and chronic lymphocytic leukemia, respectively. These and other unlabeled MAbs kill tumor cells by mediating complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (.) and by directly causing apoptosis (.,.).作者: hauteur 時(shí)間: 2025-3-29 21:52 作者: aggrieve 時(shí)間: 2025-3-30 03:51
Der Lehrer als Held?,d ein Funktionswandel heroischer Motive angezeigt, der sich auch als forcierte Fortschreibung einer literarischen Behandlung des Themas interpretieren l??t, wie sie sich bereits zu Beginn des 20. Jahrhunderts abzeichnet. Die aus dieser Epoche vorgestellten Versuche einer emphatischen Wiederbelebung
